Buy & Sell FedEx Corporation (FDX) – FedEx Corporation Price Today
Key Stats
- $78.98BMarket Cap
- IndustrialsSector
- -11.29%3M Drawdown
- $112.99BEnterprise Value
- 1.75%Dividend Yield
- 83 daysTypical Hold Time
FedEx Corporation (FDX) is currently valued at a market capitalization of $78.98B, with an enterprise value of $112.99B. Over the past 52 weeks, FedEx Corporation has traded between a low of $174.81 and a high of $338.49, highlighting its annual price range. Over the past three months, FedEx Corporation has recorded a drawdown of -11.29%, reflecting recent price volatility. FedEx Corporation offers a dividend yield of 1.75%, with the most recent dividend of $1.45 paid on 09 Mar 26. On average, investors hold FedEx Corporation for approximately 83 days, indicating typical investor behavior on the platform.
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Most Recent News
American Airlines suspends six domestic routes this summer amid rising fuel costs linked to Iran conflict
American Airlines will temporarily suspend six domestic routes from August to September due to rising jet fuel costs driven by the Iran conflict. The affected routes include flights from Los Angeles to Cleveland, Columbus, Pittsburgh, and Washington ...

OpenAI plans major upgrade to boost ChatGPT amid IPO and competition with Anthropic.
OpenAI is preparing its biggest upgrade yet, transforming ChatGPT into a superapp with multiple tools like coding and AI agents to better compete with Anthropic. This move aims to attract more corporate clients and increase revenue as OpenAI readies ...

Repatha cuts first major cardiovascular event risk by 29% in high-risk diabetes patients, new trial data show
New Phase 3 VESALIUS-CV trial data reveal that Repatha (evolocumab), added to statins, reduces the risk of first major cardiovascular events by 29% in patients with high-risk diabetes and elevated LDL cholesterol. The study involved 6,002 patients wi...
